All lobbying filings

VIATRIS INC.

VIATRIS INC. filed a Q1 report for VIATRIS INC on April 21, 2025.

Lobbying for VIATRIS INC

All filings by VIATRIS INC. · Everything VIATRIS INC has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$590,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Pennsylvania

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Health Issues

Part D Formulary Design and Generic Drug Tiering S. 1302 - Increasing Transparency in Generic Drug Applications Act H.R. 1843 - Increasing Transparency in Generic Drug Applications Act S. 775 - Increasing Transparency in Generic Drug Applications Act HR1503/S. 2916, Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act H.R. 5461 Ensuring Access to Lower-Cost Medicies for Seniors Act Drug Shortages S. 891, the Bipartisan Health Care Act

IP Issues related to generic medicines Patent Settlements S 2220, The PREVAIL Act

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S4638 2025 National Defense Authorization Act

Budget/Appropriations

HR 9747 Countinuing Appropriations and Extensions Act of 2025 (Title II, all provisions relating to Health Extenders)

Bills named in this filing 9

S. 1302
Increasing Transparency in Generic Drug Applications Act
H.R. 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S. 775
Increasing Transparency in Generic Drug Applications Act
H.R. 1503
Prescription Information Modernization Act of 2023
S. 2916
Prescription Information Modernization Act of 2023
S. 2129
Ensuring Access to Lower-Cost Medicines for Seniors Act
H.R. 5461
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023
S. 891
Bipartisan Health Care Act
H.R. 9747
Continuing Appropriations and Extensions Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.